Allergy pill may tame cancer infusion reactions
NCT ID NCT04198623
First seen Jan 11, 2026 · Last updated May 21, 2026 · Updated 20 times
Summary
This study tested whether montelukast (Singulair), an allergy medication, can lower the chance and severity of infusion reactions in people receiving monoclonal antibody treatments for blood cancers or disorders. Forty adults took montelukast before their regular premedication and infusion. The goal was to see if this approach reduces reactions, shortens infusion time, and eases the burden on patients and healthcare resources.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFUSION REACTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Community Cancer Institute
Clovis, California, 93611, United States
Conditions
Explore the condition pages connected to this study.